Dennis Crowley
SVP Business Development & Licensing @ Baxter International
Dennis Crowley is a Series C investor at Baxter International focused on Sensor and Medical. Dennis Crowley
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Dennis Crowley invests in
Stages Dennis Crowley invests in
Countries Dennis Crowley invests in
Investment Focus
Industry
- Sensor 1 (100%)
- Medical 1 (100%)
- Biometrics 1 (100%)
- Health Care 1 (100%)
- Medical Device 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Medasense
|
Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedicationMedasense’s flagship product, the PMD-200 with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of artificial intelligence and aproprietary non-invasive sensor platform. The PMD-200 is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate – a $5B market. The company’s pipeline cloud-based solutions for clinics and home, leveraging the NOL technology, addresses an additional $15B global market.The PMD-200 is distributed in Europe exclusively by Medtronic (NYSE:MDT), is cleared for marketing also in Canada, Latin America and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid-sparing.Medasense was founded in 2008 and based in Ramat Gan, Tel Aviv, Israel. | $18M / Series C / Sep 22, 2020 |
Co-Investors
About Baxter International
Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.The company operates through three segments: BioScience, Medication Delivery, and Renal.- The BioScience segment manufacturesrecombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products and technologies used in adult stem-cell therapies; and vaccines.- The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs, intravenous nutrition products; infusion pumps; and inhalation anesthetics. This segment also offers products and services related to pharmacy compounding, drug formulation, and packaging technologies.- The Renal segment provides products to treat end-stage renal disease and irreversible kidney failure. This segment also offers solutions and other products for peritoneal dialysis, a home-based therapy and product for hemodialysis, which is conducted in a hospital or clinic.Baxter International Inc. has collaborations with HHD LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. for the development of a home hemodialysis machine. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and patients at home under physician supervision.The company was founded in 1931 and is headquartered in Deerfield, Illinois.
Baxter International Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ellen McIntosh
SVP, Associate General Counsel
|
|||
David Ferguson
General Manager, Medication Delivery Global Business Unit
|
|||
David Roman
Vice President, Strategy & FP&A
|
|||
|
Dennis Crowley
SVP Business Development & Licensing
|
|||
Giuseppe Accogli
SVP & President Global Businesses
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Dennis Crowley invest in?
Dennis Crowley invests primarily in Sensor, Medical and Biometrics startups, most often at Series C stage. Most of the 1 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dennis Crowley last invest?
The most recent investment recorded for Dennis Crowley closed in Sep 2020. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
